| Characteristics (n = 93) . | Median (range) . |
|---|---|
| Age (yr) | 60.1 (23–85) |
| Male/female | 58/35 |
| Sokal risk (low/int./high) | 59/24/4 |
| EUTOS risk (low/high) | 73/5 |
| Prior IFN-α (+/−) | 19/74 |
| CML duration (mo) | 84.8 (13.2–229.4) |
| Duration of IM treatment (mo) | 75.7 (12.6–122.4) |
| Actual daily IM dose (mg/d) | 400 (66.7–400) |
| Median time to CCyR (mo) | |
| From diagnosis to CCyR | 6.6 (1–103.3) |
| From IM therapy to CCyR | 5.3 (0.5–76.7) |
| Median time to MMR (mo) | |
| From diagnosis to MMR | 19.5 (4.4–185.6) |
| From IM therapy to MMR | 17.0 (3.2–93.9) |
| Characteristics (n = 93) . | Median (range) . |
|---|---|
| Age (yr) | 60.1 (23–85) |
| Male/female | 58/35 |
| Sokal risk (low/int./high) | 59/24/4 |
| EUTOS risk (low/high) | 73/5 |
| Prior IFN-α (+/−) | 19/74 |
| CML duration (mo) | 84.8 (13.2–229.4) |
| Duration of IM treatment (mo) | 75.7 (12.6–122.4) |
| Actual daily IM dose (mg/d) | 400 (66.7–400) |
| Median time to CCyR (mo) | |
| From diagnosis to CCyR | 6.6 (1–103.3) |
| From IM therapy to CCyR | 5.3 (0.5–76.7) |
| Median time to MMR (mo) | |
| From diagnosis to MMR | 19.5 (4.4–185.6) |
| From IM therapy to MMR | 17.0 (3.2–93.9) |
CCyR, complete cytogenetic response; EUTOS, European Treatment and Outcome Study; IM, imatinib; int., intermediate; MMR, major molecular response.